How much did NewGLab Pharma Co achieve in EBIT for the current year?
In the current year, NewGLab Pharma Co has achieved an EBIT of -13.72 B KRW.
NewGLab Pharma Co EBIT 2024
NewGLab Pharma Co EBIT
-13.72 B KRW
Ticker
214870.KQ
ISIN
KR7214870008
In 2024, NewGLab Pharma Co's EBIT was -13.72 B KRW, a -52.85% increase from the -29.11 B KRW EBIT recorded in the previous year.
The NewGLab Pharma Co EBIT history
| YEAR | EBIT (undefined KRW) |
|---|---|
| 2023 | -13.72 |
| 2022 | -29.11 |
| 2021 | -28.05 |
| 2020 | -17.43 |
| 2019 | -1.42 |
| 2018 | -5.56 |
| 2017 | -6 |
| 2016 | -2.68 |
| 2015 | 4.1 |
| 2014 | 3.77 |
| 2013 | 7.01 |
NewGLab Pharma Co Revenue, EBIT, Net Income KR7214870008 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into NewGLab Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by NewGLab Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects NewGLab Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of NewGLab Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into NewGLab Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing NewGLab Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on NewGLab Pharma Co’s growth potential.
NewGLab Pharma Co Revenue, EBIT and net profit per share
| Date | NewGLab Pharma Co Revenue | NewGLab Pharma Co EBIT | NewGLab Pharma Co Net Income |
|---|---|---|---|
| 2023 | 12.62 B undefined | -13.72 B undefined | 1.99 B undefined |
| 2022 | 21.71 B undefined | -29.11 B undefined | -69.55 B undefined |
| 2021 | 29.35 B undefined | -28.05 B undefined | -50.51 B undefined |
| 2020 | 54.42 B undefined | -17.43 B undefined | -22.61 B undefined |
| 2019 | 95.82 B undefined | -1.42 B undefined | -4.01 B undefined |
| 2018 | 18.64 B undefined | -5.56 B undefined | -7.36 B undefined |
| 2017 | 30.6 B undefined | -6 B undefined | -9.12 B undefined |
| 2016 | 32.88 B undefined | -2.68 B undefined | -1.09 B undefined |
| 2015 | 73.47 B undefined | 4.1 B undefined | 3.36 B undefined |
| 2014 | 66.06 B undefined | 3.77 B undefined | 2.66 B undefined |
| 2013 | 71.25 B undefined | 7.01 B undefined | 5.73 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 71.25 B KRW | 7.01 B KRW | 5.73 B KRW |
| 2014 | 66.06 B KRW | 3.77 B KRW | 2.66 B KRW |
| 2015 | 73.47 B KRW | 4.1 B KRW | 3.36 B KRW |
| 2016 | 32.88 B KRW | -2.68 B KRW | -1.09 B KRW |
| 2017 | 30.6 B KRW | -6 B KRW | -9.12 B KRW |
| 2018 | 18.64 B KRW | -5.56 B KRW | -7.36 B KRW |
| 2019 | 95.82 B KRW | -1.42 B KRW | -4.01 B KRW |
| 2020 | 54.42 B KRW | -17.43 B KRW | -22.61 B KRW |
| 2021 | 29.35 B KRW | -28.05 B KRW | -50.51 B KRW |
| 2022 | 21.71 B KRW | -29.11 B KRW | -69.55 B KRW |
| 2023 | 12.62 B KRW | -13.72 B KRW | 1.99 B KRW |
NewGLab Pharma Co stock margins KR7214870008 ·
The NewGLab Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NewGLab Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NewGLab Pharma Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the NewGLab Pharma Co's sales revenue. A higher gross margin percentage indicates that the NewGLab Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the NewGLab Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the NewGLab Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the NewGLab Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the NewGLab Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the NewGLab Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
NewGLab Pharma Co Margin History
| NewGLab Pharma Co Gross margin | NewGLab Pharma Co Profit margin | NewGLab Pharma Co EBIT margin | NewGLab Pharma Co Profit margin |
|---|---|---|---|
| 2023 | 7.57 % | -108.73 % | 15.78 % |
| 2022 | 16.38 % | -134.06 % | -320.35 % |
| 2021 | 11.41 % | -95.57 % | -172.08 % |
| 2020 | 16.99 % | -32.03 % | -41.55 % |
| 2019 | 27.71 % | -1.48 % | -4.18 % |
| 2018 | -0.02 % | -29.8 % | -39.5 % |
| 2017 | 0.74 % | -19.59 % | -29.78 % |
| 2016 | 6.96 % | -8.15 % | -3.31 % |
| 2015 | 12.83 % | 5.58 % | 4.58 % |
| 2014 | 13.72 % | 5.71 % | 4.03 % |
| 2013 | 17.95 % | 9.84 % | 8.04 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 17.95 % | 9.84 % | 8.04 % |
| 2014 | 13.72 % | 5.71 % | 4.03 % |
| 2015 | 12.83 % | 5.58 % | 4.58 % |
| 2016 | 6.96 % | -8.15 % | -3.31 % |
| 2017 | 0.74 % | -19.59 % | -29.78 % |
| 2018 | -0.02 % | -29.8 % | -39.5 % |
| 2019 | 27.71 % | -1.48 % | -4.18 % |
| 2020 | 16.99 % | -32.03 % | -41.55 % |
| 2021 | 11.41 % | -95.57 % | -172.08 % |
| 2022 | 16.38 % | -134.06 % | -320.35 % |
| 2023 | 7.57 % | -108.73 % | 15.78 % |
NewGLab Pharma Co Aktienanalyse
What does NewGLab Pharma Co do?
NewGLab Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing NewGLab Pharma Co's EBIT
NewGLab Pharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of NewGLab Pharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
NewGLab Pharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in NewGLab Pharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about NewGLab Pharma Co stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company NewGLab Pharma Co.
How has the EBIT of NewGLab Pharma Co developed in recent years?
The EBIT of NewGLab Pharma Co has increased by -52.85% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company NewGLab Pharma Co?
The EBIT of NewGLab Pharma Co is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does NewGLab Pharma Co pay?
Over the past 12 months, NewGLab Pharma Co paid a dividend of 25 KRW . This corresponds to a dividend yield of about 0.36 %. For the coming 12 months, NewGLab Pharma Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of NewGLab Pharma Co?
The current dividend yield of NewGLab Pharma Co is 0.36 %.
When does NewGLab Pharma Co pay dividends?
NewGLab Pharma Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of NewGLab Pharma Co?
NewGLab Pharma Co paid dividends every year for the past 0 years.
What is the dividend of NewGLab Pharma Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is NewGLab Pharma Co located?
NewGLab Pharma Co is assigned to the 'Information technology' sector.
Wann musste ich die Aktien von NewGLab Pharma Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of NewGLab Pharma Co from 4/20/2016 amounting to 50 KRW, you needed to have the stock in your portfolio before the ex-date on 12/29/2015.
When did NewGLab Pharma Co pay the last dividend?
The last dividend was paid out on 4/20/2016.
What was the dividend of NewGLab Pharma Co in the year 2023?
In the year 2023, NewGLab Pharma Co distributed 0 KRW as dividends.
In which currency does NewGLab Pharma Co pay out the dividend?
The dividends of NewGLab Pharma Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von NewGLab Pharma Co
Our stock analysis for NewGLab Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewGLab Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- NewGLab Pharma Co Revenue
- NewGLab Pharma Co Net Income
- NewGLab Pharma Co P/E
- NewGLab Pharma Co P/S
- NewGLab Pharma Co EBIT
- NewGLab Pharma Co Dividend
- NewGLab Pharma Co Stocks
- NewGLab Pharma Co Market capitalization
- NewGLab Pharma Co Debt
- NewGLab Pharma Co Liabilities
- NewGLab Pharma Co Equity
- NewGLab Pharma Co AAQS
- NewGLab Pharma Co Employees
- NewGLab Pharma Co ROE
- NewGLab Pharma Co ROA
- NewGLab Pharma Co ROCE